ストックスクリーナーアプリを入手
187.57
2.03%
3.73
アフターアワーズ：
187.57
前日終値:
$183.84
開ける：
$186.16
24時間の取引高:
798.63K
Relative Volume:
0.64
時価総額：
$27.53B
収益：
$9.53B
当期純損益:
$1.29B
株価収益率:
21.30
EPS:
8.8057
ネットキャッシュフロー:
$1.97B
1週間 パフォーマンス:
+2.14%
1か月 パフォーマンス:
-2.22%
6か月 パフォーマンス:
+33.90%
1年 パフォーマンス:
+35.56%
1日の値動き範囲:
$185.54
$190.09
1週間の範囲:
$180.33
$192.28
52週間の値動き範囲:
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
Compare BIIB vs LLY, JNJ, ABBV, AZN, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
187.57 | 26.98B | 9.53B | 1.29B | 1.97B | 8.8057 |
LLY
Lilly Eli Co
|
886.63 | 784.58B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
242.49 | 579.15B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
213.12 | 370.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
193.88 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
118.10 | 295.77B | 64.93B | 18.26B | 12.36B | 7.2751 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-10 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2025-11-06 | アップグレード | Stifel | Hold → Buy |
| 2025-09-25 | 開始されました | Jefferies | Buy |
| 2025-07-21 | 再開されました | Truist | Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-04-04 | ダウングレード | Argus | Buy → Hold |
| 2025-02-11 | 開始されました | Bernstein | Mkt Perform |
| 2025-01-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-11-18 | ダウングレード | Needham | Buy → Hold |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-31 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-14 | 繰り返されました | Needham | Buy |
| 2024-02-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-12-20 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-12-07 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-24 | 繰り返されました | UBS | Buy |
| 2023-05-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-04-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | アップグレード | Goldman | Neutral → Buy |
| 2022-10-13 | アップグレード | Stifel | Hold → Buy |
| 2022-10-07 | アップグレード | Argus | Hold → Buy |
| 2022-09-28 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-28 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-04 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-04 | 繰り返されました | Cowen | Outperform |
| 2022-02-04 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-04 | 繰り返されました | Needham | Buy |
| 2022-02-04 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-04 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 繰り返されました | Robert W. Baird | Neutral |
| 2022-02-04 | 繰り返されました | Wedbush | Neutral |
| 2022-02-04 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-02-04 | 繰り返されました | Wolfe Research | Peer Perform |
| 2022-01-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-01-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-06-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 繰り返されました | Truist | Buy |
| 2021-06-11 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | アップグレード | UBS | Neutral → Buy |
| 2021-06-08 | アップグレード | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 繰り返されました | Barclays | Equal Weight |
| 2021-06-08 | アップグレード | Citigroup | Sell → Neutral |
| 2021-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-08 | 繰り返されました | Jefferies | Buy |
| 2021-06-08 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-06-08 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 繰り返されました | Stifel | Buy |
| 2021-06-08 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-06-07 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-06-07 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-01-29 | アップグレード | Stifel | Hold → Buy |
| 2020-11-10 | アップグレード | DZ Bank | Hold → Buy |
| 2020-11-09 | ダウングレード | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-11-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-04 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-11-04 | アップグレード | Jefferies | Hold → Buy |
| 2020-11-04 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-07-27 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-04-23 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-27 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | ダウングレード | Robert W. Baird | Neutral → Underperform |
すべてを表示
Biogen Inc (BIIB) 最新ニュース
Biogen Stock Pops After FDA Approves New High-Dose Spinraza For Spinal Muscular Atrophy - benzinga.com
Biogen high-dose Spinraza approval seen supporting long-term growth - Proactive financial news
US Stocks: Biogen gets FDA approval for higher dose of genetic disorder drug, shares rise 3% - The Economic Times
Biogen stock maintained at Buy by Jefferies on FDA Spinraza approval - investing.com
BMO reiterates Biogen stock rating on Spinraza approval, trial data - investing.com
Morgan Stanley reiterates Biogen stock Equalweight rating on lupus drug data - investing.com
Global markets live: Eli Lilly, Sysco, Biogen, Apple, Boohoo… - marketscreener.com
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $185 to $215 - Moomoo
US FDA approves higher dose of Biogen's genetic disorder drug - Reuters
Orphan Drugs Market is expected to Hit US$ 486.51 billion by 2032 | - openPR.com
FDA approval for SMA dosing option pulls Biogen stock lower amid weak momentum and heavy selling - Traders Union
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy - Biogen
Biogen’s second positive Phase II litifilimab trial in CLE - The Pharma Letter
6 FDA Decisions To Watch in Q2 2026 - BioSpace
TD Cowen Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $215 - Moomoo
Biogen Inc. $BIIB Stake Lowered by Fluent Financial LLC - MarketBeat
Biogen Inc (LTS:0R1B) Bonds - gurufocus.com
Biogen reports positive Phase 2 results for lupus skin drug - investing.com
New lupus medicine research sends Biogen stock down 3.78% amid near-term bearish technicals - Traders Union
Biogen Reports Positive Phase 2 AMETHYST Study Results for Litifilimab in Treating Cutaneous Lupus Erythematosus - Quiver Quantitative
Biogen Announces Positive Phase 2 Results for Litifilimab in Cutaneous Lupus Erythematosus at AAD 2026 - dermatologytimes.com
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity - Biogen
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity - GlobeNewswire Inc.
New Alzheimer’s treatment data release sends Biogen stock down 3.78% - Traders Union
Should Biogen’s ALT-B4 Alzheimer’s Delivery Deal Reshape How BIIB Investors View Its Risk Profile? - simplywall.st
Biogen Stock (BIIB) Opinions on Alteogen Partnership - Quiver Quantitative
Nordea Investment Management AB Trims Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen Beats Investor Suit Over Dozens Of Drug Claims - Law360
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Biogen Advances Litifilimab Delivery Study, Sharpening Its Autoimmune Launch Strategy - TipRanks
Biogen Hybrozyme Deal Links Subcutaneous Biologics Push With Valuation Gap - simplywall.st
Stableford Capital II LLC Acquires New Shares in Biogen Inc. $BIIB - MarketBeat
Discipline and Rules-Based Execution in BIIB Response - Stock Traders Daily
Dakota Wealth Management Boosts Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Inc (BSP:BIIB34) Stock Price, Trades & News - GuruFocus
Biotech Stocks Facing FDA Decision In April 2026 - RTTNews
Korea roundup: Alteogen, Celltrion lead biotech deals - BioWorld MedTech
Vanguard disaggregates holdings; reports 0 shares in Biogen (NASDAQ: BIIB) - Stock Titan
Fed Meeting: Is Biogen Inc stock undervalued right nowLong Setup & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Alteogen licenses drug delivery tech to Biogen for $579 million By Investing.com - za.investing.com
SG Americas Securities LLC Has $32.35 Million Holdings in Biogen Inc. $BIIB - MarketBeat
Korea's Alteogen signs $549 M deal with Biogen to develop Hybrozyme™-based subcutaneous biologics - BioSpectrum Asia
Biogen Added To Alteogen’s Long List Of Partners - Citeline News & Insights
Alteogen surges on Biogen SC deal, reclaims No.2 on South Korea’s KOSDAQCHOSUNBIZ - Chosunbiz
Hana Securities backs Alteogen as Biogen SC deal sparks Korea growth hopes - Chosunbiz
Biogen Inc. stock under pressure from Leqembi real-world data and pipeline updates at Nasdaq - AD HOC NEWS
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Bank Watch: Is now the right time to enter Biogen IncBreakout Watch & Entry Point Confirmation Signals - baoquankhu1.vn
ALTEOGEN INCBIOGEN HAS THE OPTION TO DEVELOP A THIRD PRODUCT UNDER THE AGREEMENT - Intellectia AI
Spinal Muscular Atrophy Clinical Trial Pipeline Expands as 18+ - openPR.com
Biogen inks licensing pact for injectables (BIIB:NASDAQ) - Seeking Alpha
Biogen Inc (BIIB) 財務データ
収益
当期純利益
現金流量
EPS
2.08%
2.70%
大文字化:
|
ボリューム (24 時間):